117 related articles for article (PubMed ID: 37653634)
1. QSAR Research of Novel Tetrandrine Derivatives against Human Hepatocellular Carcinoma.
Wang M; Qiu B; Wang W; Li X; Huo H
Anticancer Agents Med Chem; 2023; 23(19):2146-2153. PubMed ID: 37653634
[TBL] [Abstract][Full Text] [Related]
2. QSAR Study of Novel 1, 8-Naphthimide Derivatives Targeting Nuclear DNA.
Lian Z; Tai Y; Xia H; Zhai H
Anticancer Agents Med Chem; 2023; 23(6):726-733. PubMed ID: 36017845
[TBL] [Abstract][Full Text] [Related]
3. 2D, 3D-QSAR study and docking of vascular endothelial growth factor receptor 3 (VEGFR3) inhibitors for potential treatment of retinoblastoma.
Ren R; Gao L; Li G; Wang S; Zhao Y; Wang H; Liu J
Front Pharmacol; 2023; 14():1177282. PubMed ID: 37089961
[No Abstract] [Full Text] [Related]
4. 3D- and 2D-QSAR models' study and molecular docking of novel nitrogen-mustard compounds for osteosarcoma.
Zhuo W; Lian Z; Bai W; Chen Y; Xia H
Front Mol Biosci; 2023; 10():1164349. PubMed ID: 37065446
[No Abstract] [Full Text] [Related]
5. 3D,2D-QSAR study and docking of novel quinazolines as potential target drugs for osteosarcoma.
Lian Z; Sang C; Li N; Zhai H; Bai W
Front Pharmacol; 2023; 14():1124895. PubMed ID: 36895941
[No Abstract] [Full Text] [Related]
6. Exploration of 2D and 3D-QSAR analysis and docking studies for novel dihydropteridone derivatives as promising therapeutic agents targeting glioblastoma.
Pan M; Cheng L; Wang Y; Lyu C; Hou C; Zhang Q
Front Pharmacol; 2023; 14():1249041. PubMed ID: 37719847
[No Abstract] [Full Text] [Related]
7. In silico design of novel CDK2 inhibitors through QSAR, ADMET, molecular docking and molecular dynamics simulation studies.
Moussaoui M; Baassi M; Baammi S; Soufi H; Salah M; Daoud R; El Allali A; Belghiti ME; Belaaouad S
J Biomol Struct Dyn; 2023; 41(23):13646-13662. PubMed ID: 37203327
[TBL] [Abstract][Full Text] [Related]
8. Computational Studies of bis-2-Oxoindoline Succinohydrazides and their In Vitro Cytotoxicity.
Jarapula R; Badavath VN; Rekulapally S; Manda S
Curr Comput Aided Drug Des; 2020; 16(3):270-280. PubMed ID: 30652647
[TBL] [Abstract][Full Text] [Related]
9. Docking and QSAR Studies of 1,4-Dihydropyridine Derivatives as Anti- Cancer Agent.
Mollazadeh S; Shamsara J; Iman M; Hadizadeh F
Recent Pat Anticancer Drug Discov; 2017; 12(2):174-185. PubMed ID: 28137213
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, Molecular Docking, and 2D-QSAR Modeling of Quinoxaline Derivatives as Potent Anticancer Agents against Triple-negative Breast Cancer.
Kaushal T; Khan S; Fatima K; Luqman S; Khan F; Negi AS
Curr Top Med Chem; 2022; 22(10):855-867. PubMed ID: 35331094
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
Kale MA; Sonwane GM
Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
[TBL] [Abstract][Full Text] [Related]
12. Rational Design of Colchicine Derivatives as anti-HIV Agents via QSAR and Molecular Docking.
Worachartcheewan A; Songtawee N; Siriwong S; Prachayasittikul S; Nantasenamat C; Prachayasittikul V
Med Chem; 2019; 15(4):328-340. PubMed ID: 30251609
[TBL] [Abstract][Full Text] [Related]
13. Prediction on the inhibition ratio of pyrrolidine derivatives on matrix metalloproteinase based on gene expression programming.
Li Y; You G; Jia B; Si H; Yao X
Biomed Res Int; 2014; 2014():210672. PubMed ID: 24971318
[TBL] [Abstract][Full Text] [Related]
14. A simple and robust model to predict the inhibitory activity of α-glucosidase inhibitors through combined QSAR modeling and molecular docking techniques.
Izadpanah E; Riahi S; Abbasi-Radmoghaddam Z; Gharaghani S; Mohammadi-Khanaposhtanai M
Mol Divers; 2021 Aug; 25(3):1811-1825. PubMed ID: 33565001
[TBL] [Abstract][Full Text] [Related]
15. QSAR and molecular docking studies on designing potent inhibitors of SARS-CoVs main protease.
Song F; Sun H; Ma X; Wang W; Luan M; Zhai H; Su G; Liu Y
Front Pharmacol; 2023; 14():1185004. PubMed ID: 37266150
[No Abstract] [Full Text] [Related]
16. Design and synthesis of novel tetrandrine derivatives as potential anti-tumor agents against human hepatocellular carcinoma.
Lan J; Wang N; Huang L; Liu Y; Ma X; Lou H; Chen C; Feng Y; Pan W
Eur J Med Chem; 2017 Feb; 127():554-566. PubMed ID: 28109948
[TBL] [Abstract][Full Text] [Related]
17. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
18. Structure-based QSAR, molecule design and bioassays of protease-activated receptor 1 inhibitors.
Zhong W; Liu P; Zhang Q; Li D; Lin J
J Biomol Struct Dyn; 2017 Oct; 35(13):2853-2867. PubMed ID: 27809674
[TBL] [Abstract][Full Text] [Related]
19. Quantitative Structure-activity Relationship Study of Betulinic Acid Derivatives Against HIV using SMILES-based Descriptors.
Worachartcheewan A; Toropova AP; Toropov AA; Siriwong S; Prapojanasomboon J; Prachayasittikul V; Nantasenamat C
Curr Comput Aided Drug Des; 2018; 14(2):152-159. PubMed ID: 29332601
[TBL] [Abstract][Full Text] [Related]
20. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19.
Si Y; Xu X; Hu Y; Si H; Zhai H
Chem Biol Drug Des; 2021 Apr; 97(4):978-983. PubMed ID: 33386649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
